WENDY O'NEAL: Open Payments
NPI 1013646116 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,030 in 68 payments from 13 companies in 2025. Trend: 2023 $130 · 2024 $982 · 2025 $1,030
Food & beverage: $1,030
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $273 |
| AstraZeneca Pharmaceuticals LP | 11 | $197 |
| GlaxoSmithKline, LLC. | 6 | $113 |
| Sumitomo Pharma America, Inc. | 5 | $93 |
| Lilly USA, LLC | 5 | $74 |
| PFIZER INC. | 4 | $65 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $40 |
| Exact Sciences Corporation | 2 | $34 |
Products named: AIRSUPRA, TRELEGY ELLIPTA, UBRELVY, BOTOX, GEMTESA, MOUNJARO, VRAYLAR, XIFAXAN.
Industry payments across AL — which companies pay providers there.
